Miles Congreve

Biochemistry, Genetics and Molecular Biology · Life Sciences

44h-index21.3kcitations221works3737.72yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(49), Computational Drug Discovery Methods(33), Chemical Synthesis and Analysis(33), Neuropeptides and Animal Physiology(29), Click Chemistry and Applications(17)

Publications221 total

The rise of AlphaFold in drug design
Progress in medicinal chemistry·2025· 1 cited
Addendum: Accurate structure prediction of biomolecular interactions with AlphaFold 3
Nature·2024· 248 citedOpen Access
Accurate structure prediction of biomolecular interactions with AlphaFold 3
Nature·2024· 11.0k citedOpen Access
Faculty Opinions recommendation of Design, Synthesis, and Structure-Activity Relationship Optimization of Pyrazolopyrimidine Amide Inhibitors of Phosphoinositide 3-Kinase γ (PI3Kγ).
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature·2022
Novel Macrocyclic Antagonists of the CGRP Receptor Part 2: Stereochemical Inversion Induces an Unprecedented Binding Mode
ACS Medicinal Chemistry Letters·2022· 1 citedOpen Access
Faculty Opinions recommendation of Identification of a BAZ2A-Bromodomain Hit Compound by Fragment Growing.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature·2022
Faculty Opinions recommendation of Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase Inhibitors.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature·2022
Faculty Opinions recommendation of Structure-Guided Design of the First Noncovalent Small-Molecule Inhibitor of CRM1.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature·2022
Novel Macrocyclic Antagonists of the Calcitonin Gene-Related Peptide Receptor: Design, Realization, and Structural Characterization of Protein–Ligand Complexes
ACS Chemical Neuroscience·2022· 9 cited
A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M <sub>1</sub> receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease
Alzheimer s & Dementia Translational Research & Clinical Interventions·2022· 7 citedOpen Access
Faculty Opinions recommendation of Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H).
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature·2021
Author Correction: Acetylcholine prioritises direct synaptic inputs from entorhinal cortex to CA1 by differential modulation of feedforward inhibitory circuits
Nature Communications·2021· 1 citedOpen Access
From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s disease
Cell·2021· 87 citedOpen Access
Faculty Opinions recommendation of Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3β Inhibitors.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature·2021
Acetylcholine prioritises direct synaptic inputs from entorhinal cortex to CA1 by differential modulation of feedforward inhibitory circuits.
Apollo (University of Cambridge)·2021Open Access
Acetylcholine prioritises direct synaptic inputs from entorhinal cortex to CA1 by differential modulation of feedforward inhibitory circuits
Nature Communications·2021· 43 citedOpen Access
Faculty Opinions recommendation of Discovery of pemigatinib: A potent and selective fibroblast growth factor receptor (FGFR) inhibitor.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature·2021
Faculty Opinions recommendation of Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature·2021
Structure‐Based Drug Design for G Protein‐Coupled Receptors
Burger's Medicinal Chemistry and Drug Discovery·2021· 3 cited
Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M<sub>1</sub>‐acetylcholine receptor agonist: A randomized cross‐over trial
British Journal of Clinical Pharmacology·2021· 7 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Fiona H. Marshall(18), Christopher W. Murray(12), A.S. Dore(10), James C. Errey(10), Jonathan S. Mason(9), Gianni Chessari(8), Robin A. E. Carr(7), Malcolm Weir(7), Benjamin G. Tehan(7), Martyn Frederickson(7), Harren Jhoti(6), J.A. Christopher(6), Rachel McMenamin(6), N.J. Robertson(5), Edward Hurrell(5), K.A. Bennett(5), Chris de Graaf(5), Ali Jazayeri(5), Roger Cooke(5), Sahil Patel(5)